O
MRNA icon

OrbiMed’s Moderna MRNA Stock Holding History

OrbiMed’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-82,550
Closed -$14.8M – 134
2022
Q4 		$14.8M Buy
+82,550
New +$13.5M 0.28% 70

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

OrbiMed's MRNA Position: Q1 2023 in Review

OrbiMed sold out of Moderna (MRNA) in Q1 2023, closing a stake of 82,550 shares — an estimated $14.8M sold.

OrbiMed first reported a position in MRNA in Q4 2022 and held it in 1 quarter. The position peaked at $14.8M in Q4 2022. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

  • OrbiMed reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
  • OrbiMed sold 82,550 Moderna shares in Q1 2023, an estimated $14.8M.
  • OrbiMed first reported a position in Moderna in Q4 2022 and held it in 1 quarter.
  • OrbiMed's Moderna position peaked at $14.8M in Q4 2022.
  • 1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on OrbiMed's 13F filing for Q1 2023, filed 15 May 2023.